arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

biote Corp.

BTMD
$1.31 ▼ -0.01 (-0.76%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
6 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

biote Corp. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $41.0M
Dividend Yield —
Revenue Growth -2.5% ↘
Op. Margin 18.5% ↗
ROIC 67.0% ↗
FCF / Share $0.96 ↘
Trailing P/E 1.5x
Price / Book —
FCF Yield 73.6%
Debt / Equity -1.76
info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$192.22M
↓ -2.5% —
Net Income Profit after all expenses
$27.05M
↑ +756.7% —
Operating Margin Operating profit as % of sales
18.5%
↑ +15.4% 73th
FCF / Share Free cash flow per share
$0.96
↓ -14.8% —
Long-Term Debt Long-term obligations
$103.12M
↓ -5.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
74
Returns
18
Financial Health ↓
86
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters